These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29157136)

  • 1. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.
    Ravangard R; Mirzaei Z; Keshavarz K; Haghpanah S; Karimi M
    Hematology; 2018 Aug; 23(7):417-422. PubMed ID: 29157136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
    Kosaryan M; Karami H; Zafari M; Yaghobi N
    Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
    Karimi M; Haghpanah S; Farhadi A; Yavarian M
    Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
    Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
    Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
    Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
    Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
    Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
    Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
    Karimi M; Darzi H; Yavarian M
    J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
    Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
    J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
    Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
    Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
    Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
    Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea in the management of thalassemia intermedia.
    Karimi M
    Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis.
    Cario H; Wegener M; Debatin KM; Kohne E
    Ann Hematol; 2002 Aug; 81(8):478-82. PubMed ID: 12224008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
    Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
    Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.